Skip to main content
Swing Capital

Senores Pharmaceuticals Ltd

NSE: SENORES BSE: 544319

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

₹1,130
52W: ₹498 — ₹1190
PE 257 · Book ₹163 · +593% vs book
Market Cap₹5,204 Cr
Stock P/E257Price to Earnings
ROCE4.18%Return on Capital
ROE2.78%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 89.0% CAGR over last 5 years

Weaknesses

  • −Stock is trading at 7.02 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 1.95% over last 3 years.
  • −Earnings include an other income of Rs.66.4 Cr.
  • −Company has high debtors of 263 days.
  • −Working capital days have increased from -138 days to 138 days

Shareholding Pattern

Promoters45.82%
FIIs3.64%
DIIs9.62%
Public40.92%
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters45.77%45.78%▲0.045.78%45.8%▲0.045.81%▲0.045.82%▲0.0
FIIs4.25%4.17%▼0.13.66%▼0.54.28%▲0.63.35%▼0.93.64%▲0.3
DIIs11.77%9.66%▼2.19.51%▼0.28.62%▼0.99.32%▲0.79.62%▲0.3
Public38.2%40.39%▲2.241.03%▲0.641.3%▲0.341.54%▲0.240.92%▼0.6

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales8.9110.617.489.639.5911.8619.8235.3325.1536.81
Expenses9.448.748.2610.9712.0114.620.9833.8129.6940.29
Operating Profit-0.531.87-0.78-1.34-2.42-2.74-1.161.52-4.54-3.48
OPM %-5.95%17.62%-10.43%-13.91%-25.23%-23.1%-5.85%4.3%-18.05%-9.45%
Net Profit0.2-3.330.310.31.072.012.76.432.658.48
EPS ₹0.07-1.090.090.090.230.440.591.40.581.84

AI Insights

Revenue Trend

Mar 2026 revenue at ₹106Cr, up 171.8% YoY. OPM at -18%.

Debt Position

Borrowings at ₹85Cr. Debt-to-equity ratio: 0.12x. Healthy balance sheet.

Capex Cycle

CWIP at ₹9Cr (9% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 9.62% (-2.15pp change). FIIs: 3.64% (-0.61pp change). Promoters hold 45.82%.

Margin & Efficiency

ROCE improving from 0% (Mar 2021) to 4% (Mar 2026). Working capital days: 138.

Valuation

PE 257x with 4.18% ROCE. Price is 593% above book value of ₹163. Dividend yield: 0%.

Recent Announcements